

Special Issue

New Molecular Insights into the Pathogenesis and Drug Development of Neurodegenerative Diseases: 2nd Edition

Message from the Guest Editors

The prevalence of neurodegenerative diseases is rapidly increasing due to the aging global population, posing a significant threat to human health and creating a societal burden; while existing drugs in the market temporarily relieve symptoms, they cannot prevent disease progression. Therefore, the development of more effective drugs for neurodegenerative diseases through efficient strategies has become an urgent priority. This Special Issue aims to collect high-quality papers featuring emerging research areas in neurodegenerative diseases, with a particular emphasis on the cellular and molecular mechanisms of disease pathogenesis. It also highlights novel drug discovery approaches targeting neurodegeneration, drug repurposing, mode of action studies on drug leads, and pharmacological evaluations of different models, such as brain organoids and animals. We hope that this Special Issue will provide a theoretical and technical basis for further preclinical and clinical studies and promote the translational application of valuable candidates as potential therapeutic agents in treating neurodegenerative diseases.

Guest Editors

Dr. Aifang Cheng

Dr. Beika Zhu

Dr. Fulin Ma

Deadline for manuscript submissions

31 October 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/235396

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).